Friday, 20 Oct 2017

Drug Safety

Datesort ascending Type Title Save
29 Apr 2017 Social RT @DrRachelTate: Consider guaifenesin (one tablet with MTX dosing and one tablet 12 hours later) to ameliorate MTX neuro AEs. Dr. Cush @Rh…
29 Apr 2017 Social #SOTA2017 Dr. Bingham THe PMR and myositis cases seen did respond to our usual therapies
29 Apr 2017 Social #SOTA2017 Dr Bingham lecture on IRAE (immune related adverse events) w/ ICI is seminal info on a burgeoning problem that affects all Rheums
29 Apr 2017 Social #SOTA2017 Dr Bingham these pts required allot more steroids https://t.co/nGjTMtcZJK
29 Apr 2017 Social #SOTA2017 Dr. Bingham Most common joints are large - knees ankels shoulders, many w/ Small - MCPs PIPs wrists, ReA in 2 pts
29 Apr 2017 Social #SOTA2017 Dr. Bingham, seen only a few +ANA, all neg for RF, CCP, Joint fluid WBC 9-28K, PMN predominant, Imaging effusions, synovitis
29 Apr 2017 Social #SOTA2017 Dr Bingham John's Hopkins case experiences, pts tx for metastatic refractory cancer with ICI https://t.co/ep2D2tunPf
29 Apr 2017 Social RT @DrRachelTate: "Confusion with effusion!" Dr. Bingham describes multiple ways of reporting adverse events/arthralgia @RheumNow #SOTA2017…
29 Apr 2017 Social #SOTA2017 Dr Bingham here's example case. Develop urethritis, sinusitis, oligoarthritis on pred 120/d, inflammatory… https://t.co/dXRFknUOyF
29 Apr 2017 Social RT @DrRachelTate: "When we activate the immune system we can see immune responses unrelated to malignancy" C. Bingham, MD @RheumNow #SOTA20…
29 Apr 2017 Social #SOTA2017 Dr Bingham findings from 3 melanoma trials with ICIs https://t.co/6JDDw9Bdca
29 Apr 2017 Social #SOTA2017 Dr Bingham team systematice review of PD1 PDL1 CTLA4 inhibitos and MSK manaifestions, Arthralgia <43%,myalgia <20%, Arthritis 1-7%
29 Apr 2017 Social #SOTA2017 Dr Bingham talk about therapy used to TX non rheumatic AEs with ICI, immune check point inhibitors https://t.co/j688f5njm4
28 Apr 2017 Social BSR meeting reports study of 19,162 pts on a biologic shows risk of opportunistic infections to b 1/1000 over 5+yrs https://t.co/ca3F8AZwiq
27 Apr 2017 Social If switching from po to subcut MTX (intolerance,efficacy) to improve bioavailability, best to maintain the same dose https://t.co/G1zLL72YYI
20 Apr 2017 News Paradoxical Toxicities with TNF Inhibitors
19 Apr 2017 Social Bariticinib news is crazy. FDA CR letter means NDA cant be approved in present form; more data requested, Sit & wait https://t.co/KpVNIkCLPy
13 Apr 2017 Social RT @CCalabreseDO: 2017 ACIP vaccination update: those w/liver disease (e.g. HCV) should receive hep B vaccine series https://t.co/wvHyaYFV0U
13 Apr 2017 News Acute Steroid Use Comes with Risk
12 Apr 2017 News Celecoxib Plus PPI Preferred in High Risk Patients